Neuroimaging Findings in Patients With COVID-19

Completed

• Conditions: Neuroimaging; COVID-19
• Interventions: Diagnostic Test: Neuroimaging Findings in Patients With COVID-19

• Registration Number: NCT04734223
• Lead Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Brief Summary

This study aimed to discuss the neuroimaging findings and indications, epidemiological data, laboratory values, and the relationship of these variables with mortality in patients with COVID-19.

Detailed Description

COVID-19 can present as neurological symptoms such as anosmia, headache, taste perversion, dizziness, syncope, and altered state of consciousness. It has been reported in previous studies that thromboembolic ischemic and hemorrhagic strokes associated with COVID-19 have been observed in the early period. It has been suggested that conditions characterized by neurological sequelae, such as encephalitis and encephalopathy, ataxic seizures, Guillain-Barré syndrome (GBS), demyelinating diseases, and neuromuscular disorders may occur in the longer term.In the present study, the investigators aimed to reveal the findings of neuroimaging analyses performed in patients followed up with a diagnosis of COVID-19 who had neurological symptoms, discuss the relationship of these findings with laboratory and epidemiological data, and emphasize that CNS involvement in these patients should not be overlooked. In this study, 436 patients with COVID-19 who underwent at least one neuroimaging procedure during April 2020-December 2020 due to neurological symptoms and whose diagnosis was confirmed by reverse transcriptase-polymerase chain reaction test were included. Although computed tomography was predominantly used for imaging, magnetic resonance imaging was also used when necessary. The patients were grouped based on imaging findings, and statistical evaluations were made between the groups.

Study Timeline

• Study Start: 2020-04-01
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Study First Submitted: 2021-01-29
• Status Verified: 2021-02
• Study First Submitted QC: 2021-02-01
• Last Update Submitted: 2021-02-01
• Study First Posted: 2021-02-02
• Last Update Posted: 2021-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 436

Inclusion Criteria

• COVID-19 RT-PCR positivity-
• older than 18 years old

Exclusion Criteria

• younger than 18 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 4	Neuroimaging Findings in Patients With COVID-19	The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
Group 1	Neuroimaging Findings in Patients With COVID-19	The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
Group 3	Neuroimaging Findings in Patients With COVID-19	The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
Group 2	Neuroimaging Findings in Patients With COVID-19	The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.

Primary Outcome Measures

Name	Time	Method
Frequency of acute thromboembolism in COVID-19 patients undergoing neuroimaging	Between April and December 2020	Acute thromboembolic events are common in COVID-19 subjects undergoing neuroimaging, potentially due to an increased procoagulant process.

Trial Locations

Locations (1)

Sağlik Bilimleri Üniversitesi Training and Research Hospital; 🇹🇷 Di̇yarbakir, Turkey